BRØNSTED ACIDIC IONIC LIQUID
233
3.95 (2H, q, J ¼ 7 Hz), 5.78 (1H, d, J ¼ 2.6 Hz), 5.86 (1H, s, NH), 7.08 (1H, m), 7.21
(2H, m), 7.5 (1H, d, J ¼ 8.3), 8.69 (1H, s, NH).
5-Acetyl-4-(3-methoxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-(1H)-one
(Table 2, Entry 13). FT-IR (KBr, cmꢁ1): 3340, 3273, 3051, 1714, 1678, 1599, 1487,
1
1453, 1330. H NMR (500 MHz, CDCl3=DMSO-d6): d ¼ 2.09 (3H, s), 2.34 (3H, s),
2.76 (3H, s), 5.36 (1H, s), 5.97 (1H, s, NH), 6.78 (1H, d, J ¼ 7.4 Hz), 6.83 (1H, s),
6.87 (1H, d, J ¼ 7.6 Hz), 7.23 (1H, m), 7.86 (1H, s, NH).
5-Acetyl-6-methyl-4-(3-nitrophenyl)-3,4-dihydropyrimidin-2-(1H)-one
(Table 2, Entry 14). FT-IR (KBr, cmꢁ1): 3348, 3272, 3061, 1681, 1600, 1530, 1436.
1H NMR (500 MHz, 500 MHz, CDCl3=DMSO-d6): d ¼ 2.12 (3H, s), 2.29 (3H,s),
5.43 (1H, d, J ¼ 3.4 Hz), 6.93 (1H, s, NH), 7.38 (1H, t, J ¼ 7.9 Hz), 7.58 (1H, d,
J ¼ 7.7 Hz), 7.99 (1H, d, J ¼ 7.8 Hz), 8.14 (1H, s), 8.65 (1H, s, NH).
5-Acetyl-4-(2-chlorophenyl)-6-methyl-3,4-dihydropyrimidin-2-(1H)-one
(Table 2, Entry 15). FT-IR (KBr, cmꢁ1): 3341, 3292, 1704, 1622, 1551, 1461,
1333.1H NMR (500 MHz, CDCl3=DMSO-d6): d ¼ 1.97 (3H, s), 2.52 (3H, s), 5.77
(1H,s), 5.81 (1H, s, NH), 7.18 (3H, m), 7.33 (1H, m), 8.38 (1H, s, NH).
ACKNOWLEDGMENTS
We gratefully acknowledge the funding support received for this project from
the Isfahan University of Technology (IUT), Iran (A. R. H.). Further financial sup-
port from the Center of Sensor and Green Chemistry Research (IUT) is gratefully
acknowledged.
REFERENCES
´
1. (a) Russowsky, D.; Canto, R. F.; Sanches, S. A.; D’Oca, M. J.; Fatima, A. D.; Pilli, R. A.;
Kohn, L. K.; Antonio, M. A.; Carvalho, J. A. Synthesis and differential antiproliferative
ˆ
activity of Biginelli compounds against cancer cell lines: Monastrol, oxo-monastrol and
oxygenated analogues. Bioorg. Chem. 2006, 34, 173–182; (b) Kappe, C. O. Biologically
active dihydropyrimidones of the Biginelli-type—A literature survey. Eur. J. Med. Chem.
2000, 35, 1043–1052.
2. (a) Atwal, K. S.; Swanson, B. N.; Unger, S. E.; Floyd, D. M.; Moreland, S.; Hedberg, A.;
O’Reilly, B. C. Dihydropyrimidine calcium channel blockers: 3-Carbamoyl-4-aryl-1,2,3,4-
tetrahydro-6-methyl-5 pyrimidinecarboxaycliidc esters as orally effective antihypertensive
agents. J. Med. Chem. 1991, 34, 806–811; (b) Rovnyak, G. C.; Atwal, K. S.; Hedberg, A.;
Kimball, S. D.; Moreland, S.; Gougoutas, J. Z.; O’Reilly, B. C.; Schwartz, J.; Malley, M.
F. Dihydropyrimidine calcium channel blockers, 4: Basic 3-substituted-4-aryl-1,4-
dihydropyrimidine-5-carboxyaliccid esters: Potent antihypertensive agents. J. Med. Chem.
1992, 35, 3254–3263; (c) Rovnyak, G. C.; Kimball, S. D.; Beyer, B.; Cucinotta, G.; DiMarco,
J. D.; Gougoutas, J.; Hedberg, A.; Malley, M.; McCarthy, J. P.; Zhang, R.; Morelande, S.
Calcium entry blockers and activators: Conformational and structural determinations of
dihydropyrimidine calcium channel modulators. J. Med. Chem. 1996, 38, 119–129.
3. (a) Nagarathnam, D.; Miao, S. W.; Lagu, B.; Chiu, G.; Fang, J.; Dhar, T. G. M.; Zhang, J.;
Tyagarajan, S.; Marzabadi, M. R.; Zhang, F.; Wong, W. C.; Sun, W.; Tian, D.; Wetzel,
J. M.; Forray, C.; Chang, R. S. L.; Broten, T. P.; Ransom, R. W.; Schorn, T. W.; Chen,
T. B.; O’Malley, S.; Kling, P.; Schneck, K.; Bendesky, R.; Harrell, C. M.; Vyas, K. P.;